Zobrazeno 1 - 5
of 5
pro vyhledávání: '"621"'
Autor:
Anthony R. Mato, David F. Claxton, Bruce D. Cheson, Jeffrey J. Pu, Clive S. Zent, Molly Fanning, Colleen Timlin, Lauren E. Strelec, Krista Isaack, Allan-Louie Cruz, Paul M. Barr, Nicole Lamanna, David L. Porter, Catherine Daniel, Daniel J. Landsburg, Spencer Henick Bachow, Chaitra S. Ujjani, Pavel Kiselev, Melissa Yacur, Christina Howlett, Allison M. Winter, Danielle M. Brander, Kaitlin Kennard, Chadi Nabhan, Stephen J. Schuster, Brian T. Hill, Alan P Skarbnik, Sunita D. Nasta
Publikováno v:
Blood. 128:3222-3222
Introduction: Ibrutinib (Ibr) is a kinase inhibitor (KI) indicated for treating CLL. Clinical trials that led to its approval showed that its unique side effects differ from traditional chemotherapy toxicities. We previously reported (Mato et al, ASH
Autor:
Jan Jacob Schuringa, Judith M. Vonk, Aniek O. de Graaf, Gerwin Huls, H. Marike Boezen, Isabelle A van Zeventer, Jonas B Salzbrunn, Pim van der Harst, Joop H. Jansen, Bert A. van der Reijden
Publikováno v:
Blood, 5(8), 2115-2122. AMER SOC HEMATOLOGY
Blood Adv
Blood Advances, 5, 8, pp. 2115-2122
Blood Advances, 5, 2115-2122
Blood Adv
Blood Advances, 5, 8, pp. 2115-2122
Blood Advances, 5, 2115-2122
Clonal hematopoiesis (CH), characterized by a fraction of peripheral blood cells carrying an acquired genetic variant, emerges with age. Although in general CH is associated with increased mortality and morbidity, no higher risk of death was observed
Autor:
Naveen Pemmaraju, Kate J. Newberry, Hagop M. Kantarjian, Jorge E. Cortes, Prithviraj Bose, Naval Daver, Lucia Masarova, Srdan Verstovsek
Publikováno v:
Blood. 128:4250-4250
Introduction: The Dynamic International Prognostic Scoring System-Plus (DIPPS-Plus) for primary myelofibrosis (PMF) categorizes cytogenetic abnormalities as "favorable" and "unfavorable." Abnormalities (Abn) -7/7q-; -5/5q-; i(17q), +8; inv(3); 12p-;
Autor:
Valeria Santini, Barry S. Skikne, Paresh Vyas, Stephen Songer, John Morrill, Richard Stone, Mark D. Minden, Teresa Bernal del Castillo, C.L. Beach, Hartmut Döhner, Haifa Kathrin Al-Ali, Hervé Dombret, Jerry Weaver, John F. Seymour
Publikováno v:
Blood. 128:1638-1638
Background: Karyotype is the strongest independent prognostic factor for survival in AML. The randomized phase 3 AZA-AML-001 study of older patients with AML showed AZA prolonged overall survival (OS) compared with CCR (10.4 vs 6.5 months, respective
Autor:
Hans Walter Lindemann, Peter Staib, Peter Brossart, Donald Bunjes, Claudia Haferlach, R. Kuse, Dieter K. Hossfeld, Nicolaus Kröger, Hartmut Döhner, Rainer Schwerdtfeger, Gabriela M. Baerlocher, Dietrich W. Beelen, Alois Gratwohl, Andreas Hochhaus, Hans-Jochem Kolb, Martin C. Müller, Michele Baccarani, Ruediger Hehlmann, Christian Dietz, Herrad Baumann, Brigitte Schlegelberger, Andreas Reiter, Bernd Hertenstein, Christof Scheid, J Novotny, Michael Lauseker, Lida Kalmanti, Susanne Saussele, Axel R. Zander, Jiri Mayer, Karsten Spiekermann, Susanne Schnittger, Markus Pfirrmann, Joerg Hasford, Axel A. Fauser, Sebastien Rinaldetti, Renate Arnold, Michael Schatz, Matthias Edinger, Martine Jotterand, Arnold Ganser, Herbert G. Sayer, Christoph Nerl, Carlo Aul, Alice Fabarius, Christiane Falge, Matthias Bormann
Publikováno v:
Blood. 126:1581-1581
During the course of chronic myeloid leukemia (CML) progression to blast crisis (BC) is thought to be caused by genetic instability such as cytogenetic aberrations in addition to the translocation t(9;22)(q34;q11). We have shown previously that major